Skip to main content
. 2017 Aug 2;8(39):66087–66097. doi: 10.18632/oncotarget.19798

Figure 2. The impact of RAS expressions on overall survival in AML patients.

Figure 2

(A, B and C) For KRAS expression in whole-cohort AML, non-APL AML, and CN-AML patients. (D, E and F) For NRAS expression in whole-cohort AML, non-APL AML, and CN-AML patients. (G, H and I) For RAS expression in whole-cohort AML, non-APL AML, and CN-AML patients, “both low” indicated neither KRAS nor NRAS overexpression, “either high” indicated either KRAS or NRAS overexpression, “both high” indicated both KRAS and NRAS overexpression.